Spots Global Cancer Trial Database for Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Official Title: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Study ID: NCT04354064
Interventions
Study Description
Brief Summary: Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Washington University School of Medicine, Saint Louis, Missouri, United States
Contact Details
Name: Russell Pachynski, M.D.
Affiliation: Washington University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
